Cracking the Homologous Recombination Deficiency Code: How to Identify Responders to PARP Inhibitors

Poly (ADP ribose) polymerase (PARP) inhibitors have shown substantial efficacy in BRCA-mutated ovarian cancer for several years, and their indication has gradually been extended to other tumour locations such as breast, prostate and pancreas.